

Supplemental Figure 6, Verdegaal et al.




Figure S6: The effect of IFNa conditioning on circulating immune cells. PBMC were isolated from peripheral blood collected before and 1 week after the start of IFNa treatment and used for detailed phenotypical characterization by flowcytometry (N=18). The percentage CD3+ cells (a), CD4+ (b), CD8+ (c), CD4+CD25+CD127+FoxP3+ Treg (d), CD14+HLA-DR- mMDSC (e), CD14+CD33-CD163- M1 macrophages (f), CD14+CD33-CD163+ M2 macrophages (g), and CD3-CD56+ NK cells (h), are depicted as fraction of total viable cells. i-m) Changes in percentages of different DC subsets DC1 thru CD4 and pDC, previously described by Villani (34), are depicted. The percentage CD14-/intermediate, CD16++ non-classical monocytes (n) and CD14+CD16+ intermediate monocytes (o) are given as percentage of the CD3-, CD19-, CD20- and CD56- non-T/B/NK cells. Differences within were calculated using the Wilcoxon signed rank test. **p<0,01, *** p<0,001, **** p<0,0001.